evaluation of immunohistochemistry-equivocal (2+) her2 gene status in invasive breast cancer by silver dna in situ hybridization (sish) and its association with clinicopathological variables

نویسندگان

zaidoon a. musa

al-emamain al-kadhimain medical city, baghdad, iraq ban j. qasim

dept. of pathology and forensic medicine, college of medicine, al-nahrain university, baghdad, iraq a.wahab a.k. al shaikhly

dept. of pharmacy (dean)/ al rasheed university college, baghdad, iraq

چکیده

background and objective:determination of her2 gene is crucial in breast carcinoma management and prognosis, as her2 alterations are linked to a shorter disease-free period, overall survival and resistance to tamoxifen anti-estrogen therapy and other chemotherapy regimens, regardless of the nodal or hormone receptor status. this study aimed to estimate her2 gene status of infiltrative mammary cancer cases with immunohistochemically equivocal (2+) score using silver dna in situ hybridization(sish) technique and to investigate its association with clinicopathological variables. methods: the study included 52 formalin-fixed paraffin embedded tissue blocks from female patients with invasive breast carcinoma with score of 2+ (equivocal) her2 immunohistochemistry. all cases were studied by silver dna in situ hybridization technique (sish) for the determination of the amplified her2 dna. results: thesish technique showed that her2 gene was not amplified in 33 cases out of 52 (63.5%); while the rest of 19 cases (36.5%) revealed amplified gene status.according to age, her2 gene status reported non-significant difference in the age groups between cases with amplified and non-amplified gene status (p=0.173). there was a significant negative association between positive estrogen (er) and progesterone (pr) status and her2 gene amplification (p= 0.002 and 0.017, respectively). conclusion: more than half of breast carcinoma cases with equivocal her2 immunoreactivity showed non-amplified gene status; this needs to be considered by oncologists in their management planning of breast cancer. amplified her2 gene is significantly associated with negative er and pr status that affects patients’ management protocols and future outcome of the disease.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables

Background and Objective:Determination of HER2 gene is crucial in breast carcinoma management and prognosis, as HER2 alterations are linked to a shorter disease-free period, overall survival and resistance to tamoxifen anti-estrogen therapy and other chemotherapy regimens, regardless of the nodal or hormone receptor status. This study aimed to...

متن کامل

Predicting Effects of Clinicopathological Variables on Her2 Gene Amplification by Chromogenic in situ Hybridization (CISH) in IHC Her2 (2+) Breast Cancer Patients; A Study from Iran

Background & Objective: The her2 amplification plays an important role in breast cancer management. Therefore, there is a need for using supplementary molecular methods in IHC equivocal cases. Present study has been conducted to determine the effects of clinicopathological variables on her2 gene amplification by chromogenic in situ hybridization (CISH) in IHC ...

متن کامل

the study of aaag repeat polymorphism in promoter of errg gene and its association with the risk of breast cancer in isfahan region

چکیده: سرطان پستان دومین عامل مرگ مرتبط با سرطان در خانم ها است. از آنجا که سرطان پستان یک تومور وابسته به هورمون است، می تواند توسط وضعیت هورمون های استروئیدی شامل استروژن و پروژسترون تنظیم شود. استروژن نقش مهمی در توسعه و پیشرفت سرطان پستان ایفا می کند و تاثیر خود را روی بیان ژن های هدف از طریق گیرنده های استروژن اعمال می کند. اما گروه دیگری از گیرنده های هسته ای به نام گیرنده های مرتبط به ا...

15 صفحه اول

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer

PURPOSE Amplification of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18% to 20% of breast cancers, and it is recognized as a prognostic and predictive marker. We investigated the HER2 status in Korean breast cancer by immunohistochemistry (IHC) and silver-enhanced in situ hybridization (SISH), as the first step toward building a nationwide quality assurance program for HE...

متن کامل

Concomitant Detection of HER2 Protein and Gene Alterations by Immunohistochemistry (IHC) and Silver Enhanced In Situ Hybridization (SISH) Identifies HER2 Positive Breast Cancer with and without Gene Amplification

INTRODUCTION HER2 status assessment became a mandatory test assay in breast cancer, giving prognostic and predictive information including eligibility for adjuvant anti-HER2 therapy. Precise and reliable assessment of HER2 status is therefore of utmost importance. In this study we analyzed breast cancer samples by a novel technology for concomitant detection of the HER2 protein and gene copy nu...

متن کامل

Chromogenic in situ Hybridization Compared with Real Time Quantitative Polymerase Chain Reaction to Evaluate HER2/neu Status in Breast Cancer

Background and objective: The assessment of human epidermal growth factor receptor 2 (HER2) status has become of great importance in the diagnosis of breast cancer. The aim of this study was to investigate the diagnostic value of quantitative Polymerase Chain Reaction (qPCR) and Chromogenic In Situ Hybridization (CISH) to assess HER2 status of biopsy specimens. <...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of pathology

جلد ۱۲، شماره ۱، صفحات ۹-۱۹

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023